FDA revises antidepressant black boxes
This article was originally published in Pharmaceutical Approvals Monthly
Class labeling for antidepressants is updated Aug. 2 to include warnings about increased risks of suicidality in young adults ages 18 to 24. The new language, which FDA proposed in May, states that risk was not seen in adults older than 24 and that the risk decreased for adults ages 65 and older. Also added is a statement that "Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide." The Psychopharmacologic Drugs Advisory Committee recommended the changes at a 2006 meeting on the risk of drug-related suicidality in adults. The black box warning on suicidality in pediatric patients was first added in 2005...
You may also be interested in...
The company has identified 600 sites of care to treat Alzheimer's patients with aducanumab in the US and is confident on its pricing strategy, management said.
The robotic surgery company recorded $1.29bn in first-quarter revenue, an 18% year-over-year increase. Worldwide da Vinci procedures were up 16% as surgical volumes recovered from the pandemic.
The Department of Toxic Substances Control does not identify specific chemicals of concern in its 2021-2023 Priority Product Draft Work Plan, but says it is focusing on ingredients and endpoints associated with children, women of childbearing age, communities of color and aquatic impacts.